1,2-Diazole ring (including hydrogenated)

Subclass of:

544 - Organic compounds -- part of the class 532-570 series

544000000 - ORGANIC COMPOUNDS (CLASS 532, SUBCLASS 1)

544000000 - HETEROCYCLIC CARBON COMPOUNDS CONTAINING A HETERO RING HAVING CHALCOGEN (I.E., OXYGEN, SULFUR, SELENIUM, OR TELLURIUM) OR NITROGEN AS THE ONLY RING HETERO ATOMS (Class 540, subclass 1)

544001000 - Hetero ring is six-membered having two or more ring hetero atoms of which at least one is nitrogen (e.g., selenazines, etc.)

544063000 - Six-membered hetero ring consists of oxygen, nitrogen and carbon (e.g., 1,2-oxazines, etc)

544098000 - 1,4-Oxazines

544106000 - Morpholines (i.e., fully hydrogenated 1,4-oxazines

544111000 - Additional nitrogen containing hetero ring (e.g., thiazetidine, etc.)

544132000 - Five-membered hetero ring having two or more ring hetero atoms of which at least one is nitrogen

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application number	Description	Number of patent applications / Date published
544140000	1,2-Diazole ring (including hydrogenated)	10
20100152443	PYRAZOLE DERIVATIVE, INTERMEDIATE THEREFOR, PROCESSES FOR PRODUCING THESE, AND HERBICIDE CONTAINING THESE AS ACTIVE INGREDIENT - The present invention provides a pyrazole derivative of the general formula (1),	06-17-2010
20120029192	Pyrazole Derivatives - This invention relates to pyrazole derivatives of formula (I)	02-02-2012
20120316336	4-[-2-[[5-METHYL-1-(2-NAPHTALENYL)-1H-PYRAZOL-3-YL]OXY]ETHYL]MORPHOLINE HYDROCHLORIDE POLYMORPHS AND SOLVATES - The present invention relates to polymorphs and solvates of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine (P027), processes for their preparation, and to pharmaceutical compositions comprising them.	12-13-2012
20130150575	4-[-2-[[5-METHYL-1-(2-NAPHTALENYL)-1H-PYRAZOL-3-YL]OXY]ETHYL]MORPHOLINE HYDROCHLORIDE AMORPHOUS SOLID FORMS - The present invention relates to solid forms having a low degree of crystallinity or substantially amorphous of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine (P027) and processes for their preparation.	06-13-2013
20130267704	1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 - The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that is active in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40, and to their use in a method for treating or preventing diseases based on the expression of MCP-1, CX3CR1 and p40.	10-10-2013
20140011997	NEPRILYSIN INHIBITORS - In one aspect, the invention relates to compounds having the formula:	01-09-2014
20140073783	NEPRILYSIN INHIBITORS - In one aspect, the invention relates to compounds having the formula:	03-13-2014
20140364603	NEPRILYSIN INHIBITORS - In one aspect, the invention relates to compounds having the formula:	12-11-2014
20150073141	DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO - The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT	03-12-2015
20150133658	NEPRILYSIN INHIBITORS - In one aspect, the invention relates to compounds having the formula:	05-14-2015